Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ: SPRC )

0.3693 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EST, Feb 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 31
Open 0.3693
Bid (Size) 0.3500 (1)
Ask (Size) 0.4000 (5)
Prev. Close 0.3693
Today's Range 0.3693 - 0.3693
52wk Range 0.1970 - 4.100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax’s Entry into Direct Import of JAC Electric Vehicles
From SciSparc Ltd
Via GlobeNewswire
SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology
From SciSparc Ltd
Via GlobeNewswire

Performance

YTD
-5.93%
-5.93%
1 Month
-30.40%
-30.40%
3 Month
+72.33%
+72.33%
6 Month
+0.11%
+0.11%
1 Year
-90.13%
-90.13%

More News

Read More
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico
From SciSparc Ltd
Via GlobeNewswire
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
From SciSparc Ltd
Via GlobeNewswire
SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles
From SciSparc Ltd
Via GlobeNewswire
SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results
From SciSparc Ltd
Via GlobeNewswire
Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet
Via Benzinga
S&P Jumps 1%; Regional Health Properties Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?
Via Benzinga
Exposures Product Safety
US Stocks Open Higher; Dow Jumps Over 200 Points
Via Benzinga
Topics Stocks
Exposures US Equities
SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
S&P 500 Edges Lower, SciSparc Shares Surge
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Gains 50 Points, SEALSQ Shares Plummet
Via Benzinga
Topics Stocks
Exposures US Equities
Nasdaq Dips Over 100 Points, US Initial Jobless Claims Fall
Via Benzinga
SciSparc Shares Skyrocket With AutoMax's First JAC Motors Shipment
Via Benzinga
Why Zoomcar Shares Are Trading Higher By Around 142%; Here Are 20 Stocks Moving Premarket
Via Benzinga
SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation
From SciSparc Ltd
Via GlobeNewswire
SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company
From SciSparc Ltd
Via GlobeNewswire
Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome
Via Benzinga
Exposures Product Safety
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
From SciSparc Ltd
Via GlobeNewswire
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
From SciSparc Ltd
Via GlobeNewswire
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
From SciSparc Ltd
Via GlobeNewswire
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine Files International Patent For Ibogaine Combination Therapy
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.